{"Symbol": "ABCL", "AssetType": "Common Stock", "Name": "Abcellera Biologics\u00a0Inc", "Description": "AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.", "CIK": "1703057", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "150 WEST 4TH AVE, VANCOUVER, BC, CANADA, V5Y 1G6", "OfficialSite": "https://www.abcellera.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "927939000", "EBITDA": "-232664000", "PERatio": "None", "PEGRatio": "None", "BookValue": "3.224", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.57", "RevenuePerShareTTM": "0.119", "ProfitMargin": "0", "OperatingMarginTTM": "-8.52", "ReturnOnAssetsTTM": "-0.104", "ReturnOnEquityTTM": "-0.168", "RevenueTTM": "35325000", "GrossProfitTTM": "-147487008", "DilutedEPSTTM": "-0.57", "QuarterlyEarningsGrowthYOY": "0.459", "QuarterlyRevenueGrowthYOY": "0.376", "AnalystTargetPrice": "9.83", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "6", "AnalystRatingHold": "1", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "27.47", "PriceToSalesRatioTTM": "26.27", "PriceToBookRatio": "0.966", "EVToRevenue": "16.35", "EVToEBITDA": "5.3", "Beta": "0.843", "52WeekHigh": "6.51", "52WeekLow": "1.891", "50DayMovingAverage": "3.699", "200DayMovingAverage": "3.944", "SharesOutstanding": "299335000", "SharesFloat": "204326000", "PercentInsiders": "22.969", "PercentInstitutions": "36.847", "DividendDate": "None", "ExDividendDate": "None"}